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Abstract
Background: Infective endocarditis is rarely caused by Burkholderia cepacia. This infection is known to occur
particularly in immunocompromised hosts, intravenous heroin users, and in patients with prosthetic valve
replacement. Most patients with Burkholderia cepacia endocarditis usually need surgical treatment in addition to
antimicrobial treatment.
Case Presentation: Here, we report the case of a patient who developed Burkholderia cepacia-induced native
valve endocarditis with consequent cerebral involvement without any predisposing factors; she was successfully
treated by antimicrobial agents only.
Conclusion: In this report, we also present literature review of relevant cases.
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Background
Burkholderia cepacia is a gram-negative bacillus. It is
important nosocomial pathogen that particularly infects
patients with cystic fibrosis [1] and chronic granuloma-
tous diseases[2] and is known to be resistant to many
anti-bacterial agents.
Burkholderia cepacia rarely causes endocarditis in
community settings, but it is known to cause infective
endocarditis particularly in intravenous heroin users,
and in patients with prosthetic valve replacement [3].
However, infective endocarditis caused by Burkholderia
cepacia in patients without predisposing factors is rare
[4-6].
The treatment of Burkholderia cepacia endocarditis
could be conservative, i.e., administration of antibacterial
agents, and/or surgical modality [4-13]. According to the
previous reports, most patients were prescribed tri-
methoprim-sulfamethoxazole and underwent valve sur-
gery. Notwithstanding, the mortality in cases of infective
endocarditis patients is not low despite the aggressive
treatment of infective endocarditis [3].
Here, we report the case of a patient with Burkhol-
deria cepacia endocarditis and cerebral involvement
who had no predisposing factors, and the infection was
successfully managed only by antimicrobial treatment.
Along with this case, we also present a literature review.
Case Presentation
A 77-year-old woman was transferred to our hospital
from a local hospital for loss of consciousness and disor-
ientation. She had experienced a fall 2 weeks before
admission to our hospital. Plain spine radiography had
revealed a spine compression fracture. Two days earlier,
she was admitted to a local hospital for relief from back
pain. However, during her stay at the hospital, she
developed low grade fever, aphasia, and disorientation.
She was then transferred to our hospital for further
evaluation of her symptoms that were suggestive of cere-
bral infarction. She denied any history of smoking, alco-
hol consumption, or intravenous drug use. She neither
had cardiovascular disease nor exhibited any of the risk
factors for it. Mild aphasia and hemianopsia were noted
at neurological examination. Physical examination
revealed a diastolic murmur at the mitral valve area.
The clinical manifestations were suggestive of mitral
stenosis and cerebral infarction associated with emboli,
which was considered the preliminary diagnosis. Echo-
cardiography revealed mitral stenosis with a mobile
10-mm sized mobile mass (Figure 1). Brain magnetic
resonance imaging (MRI) revealed subacute and chronic
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cerebellum (Figure 2). On day 2 of hospitalization, fever
above 38°C was noted; therefore, blood culture test was
performed. She was administered ceftriaxone (2 g/d)
and gentamicin (3 mg·kg
-1.day
-1) as an empirical treat-
ment for infective endocarditis.
Despite the empirical antimicrobial treatment, intermit-
tent low-grade fever was noted. Her blood culture was
positive for Burkholderia cepacia, and antimicrobial
susceptibility test yielded positive results for cefepime,
ceftazidime, piperacillin, ciprofloxacin and trimethoprim-
sulfamethoxazole (day 7 of hospitalization). Therefore, we
changed the antimicrobial treatment to ceftazidime
(6 g/d) from day 7.
Fever resolved completely from day 9, and blood
culture was negative for Burkholderia cepacia.A f t e r
6 weeks of ceftazidime treatment, oral ciprofloxacin was
prescribed for 2 weeks as an outpatient treatment.
After the antimicrobial treatment course was com-
pleted, infective endocarditis resolved completely; no
relapse was noted during the follow-up period for 2 years.
Discussion
Burkholderia cepacia, an opportunistic pathogen, is
resistant to disinfectants and broad-spectrum antimicro-
bial agents. This pathogen often causes nosocomial
infections in imunocompromised hosts, especially in
patients with cystic fibrosis and chronic granulomatous
diseases [3,4]. In addition, patients with cancer or
chronic renal disease may also be susceptible to Bur-
kholderia infection [14-16].
In these patients, central venous catheters are the
primary source of bacteraemia [14]. Burkholderia bacter-
emia also noted in patients undergoing haemodialysis
[15]. Burkholderia cepacia also causes infective endocar-
ditis and skin and soft tissue pathology. This pathogen
rarely causes infective endocarditis; however, there are
some reports on the occurrence of this pathology in
heroine addicts [4,10-13] and patients with prosthetic
valves and valve replacements [3-5].
In our patients, Burkholderia cepacia had infected
mitral valve despite the absence of predisposing factors
that would make her susceptible to the infection. This
case is different from the previous reports [3-13] in the
following issues. First, most of the reported cases of
Burholderia cepacia endocarditis involved the prosthetic
valve. In contrast, native valve endocarditis was relatively
less frequent [3,4,7-9]. Burholderia cepacia-induced
Figure 1 A 13-mm echogenic mobile mass can be seen
posterior to the mitral valve leaflet at 58° and 116° on the
transoesophageal echocardiogram. In addition, mitral stenosis
(valve area = 1.7 cm
2) with a thickened and partially mobile
posterior mitral valve can be seen on the transthoracic
echocardiogram.
Figure 2 Subacute and chronic infarction in both cerebral
hemisphere and cerebellum. High signal intensity on diffusion-
weighted image (arrow).
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predisposing condition, most patients with native valve
endocarditis had a history of intravenous drug abuse
[3,4,7-9] and mitral valve endocarditis has mostly been
reported in patients having prosthetic valves [3-5]. How-
ever, our patient did not exhibit any of the predisposing
factors related to this infection described previously.
Second, trimethoprim-sulfamethoxazole is commoly
used for the treatment of this infection [4-9]. However,
ceftazidime was administered to our patient because of
cerebral involvement and risk of trimethoprim-sulfa-
methoxazole allergy. Brain MRI had revealed cerebral
and cerebellar infarctions in our patient. These findings
suggest that the emboli had migrated into the cerebral
hemispheres and induced an ischemic change of the
involved regions. Therefore, an antimicrobial agent,
such as ceftazidime, that could penetrate the blood-
brain barrier was required in this case.
Antimicrobial resistance of Burkholderia cepacia has
posed a great challenge of treating the infection. This
pathogen is intrinsically resistant to aminoglycosides
and polymyxins. The antimicrobial effective against this
pathogen are carbapenem, broad-spectrum beta-lactams
(such as, piperacillin-tazobactam and ceftazidime), and
trimethoprim-sulfamethoxazole. Therefore, because of
such antimicrobial resistance, a combination of drugs
and surgical treatment for valvulopathy is required
[3-7,9]. However, we successfully treat the patient with-
out the surgical treatment.
Third, replacement of the prosthetic or native valve
has been required in most patients with infective endo-
carditis [3,7-9] but we did not need to perform any such
surgery in our patient because of the excellent response
to antimicrobial therapy. In addition, her valve function
was also apparently preserved without surgery. On the
bases of her valve function, life expectancy, and the
morbidity involved in such surgical treatment, we
decided against surgery and we were able to successfully
treat the infective endocarditis by antibiotics only.
Fourth, in patients with Burkholderia cepacia endocar-
ditis, the mitral valve is known to be less frequently
involved than the tricuspid valve; mitral valve involve-
ment has been reported in only those patients who pre-
viously had prosthetic valve replacement or valve repair
surgery [3-5], and only 1 study reported aortic valve
endocarditis without any predisposing factors [6].
In summary, we experienced a case of native valve endo-
carditis with cerebral involvement by Burkholderia cepacia
without predisposing factors of Burkholderia infection,
successfully managed by antimicrobial treatment only.
Conclusion
Infective endocarditis is rarely caused by Burkholderia
cepacia. Recently, we encountered a patient who developed
Burkholderia cepacia endocarditis and cerebral involve-
ment without the predisposing factors. We successfully
treated the patient with only antimicrobial medication;
surgical modality was not required.
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